These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3925854)

  • 1. Controlled drug release from poly(ortho esters).
    Heller J
    Ann N Y Acad Sci; 1985; 446():51-66. PubMed ID: 3925854
    [No Abstract]   [Full Text] [Related]  

  • 2. Poly(ortho ester) biodegradable polymer systems.
    Heller J; Himmelstein KJ
    Methods Enzymol; 1985; 112():422-36. PubMed ID: 3930918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable hollow fibres for the controlled release of drugs.
    Schakenraad JM; Oosterbaan JA; Nieuwenhuis P; Molenaar I; Olijslager J; Potman W; Eenink MJ; Feijen J
    Biomaterials; 1988 Jan; 9(1):116-20. PubMed ID: 3126841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting contraceptive agents: in vitro hydrolysis of esters of norethisterone and levonorgestrel.
    Naderi S; Fotherby K
    Steroids; 1983 Mar; 41(3):397-417. PubMed ID: 6419410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intravitreal drug delivery by microspheres of biodegradable polymers].
    Moritera T; Ogura Y; Honda Y; Wada R; Hyon SH; Ikada Y
    Nippon Ganka Gakkai Zasshi; 1990 May; 94(5):508-13. PubMed ID: 2220493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels.
    Ory SJ; Hammond CB; Yancy SG; Hendren RW; Pitt CG
    Am J Obstet Gynecol; 1983 Mar; 145(5):600-5. PubMed ID: 6402933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the ratio of levonorgestrel, 0.15 mg, to ethinyl estradiol, 0.03 mg.
    Christie T
    J Reprod Med; 1983 Jan; 28(1 Suppl):63-5. PubMed ID: 6403701
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-acting contraceptive agents: aliphatic and alicyclic carboxylic esters of levonorgestrel.
    Shafiee A; Vossoghi M; Savabi F; Watson TG; Schubert K; Ponsold K; Werner W; Wagner H; Vlahov R; Tarpanov V
    Steroids; 1983 Mar; 41(3):349-59. PubMed ID: 6419408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodegradable poly(ester-anhydride) for new antifouling coating.
    Faÿ F; Linossier I; Langlois V; Vallée-Rehel K
    Biomacromolecules; 2007 May; 8(5):1751-8. PubMed ID: 17425364
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-acting progestins--promise and prospects.
    Popul Rep K; 1983 May; 11(2):K17-55. PubMed ID: 6222930
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral contraception, 1986. Currently available formulations.
    Hale R
    J Reprod Med; 1986 Jun; 31(6 Suppl):557-8. PubMed ID: 3088272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of polymeric poly(epsilon-caprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids.
    Dhanaraju MD; Gopinath D; Ahmed MR; Jayakumar R; Vamsadhara C
    J Biomed Mater Res A; 2006 Jan; 76(1):63-72. PubMed ID: 16108044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian function during treatment with high ratio levonorgestrel/ethinyl estradiol as oral contraceptives.
    Johansson ED; Elamsson K; Elmestedt U
    Gynecol Obstet Invest; 1982; 14(2):97-105. PubMed ID: 6811379
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of different combinations of ethinyl estradiol & levonorgestrel on plasma lipids including high-density lipoprotein cholesterol.
    Mandal B; Maity CR
    Indian J Med Res; 1985 Apr; 81():382-6. PubMed ID: 3926642
    [No Abstract]   [Full Text] [Related]  

  • 16. [Controlled studies on the oral administration of progestagens, an antiestrogen and vitamin B6 in the treatment of mastodynias].
    Colin C
    Rev Med Brux; 1982 Nov; 3(9):605-9. PubMed ID: 6819627
    [No Abstract]   [Full Text] [Related]  

  • 17. [Regulation of fertility by means of vaginal rings medicated with estradiol and levonorgestrel].
    Díaz S; Croxatto HB; Pavez M; Miranda P; Sivin I
    Rev Chil Obstet Ginecol; 1982; 47(4):266-73. PubMed ID: 6821442
    [No Abstract]   [Full Text] [Related]  

  • 18. Subdermal progestin implant contraception.
    Darney PD
    Curr Opin Obstet Gynecol; 1991 Aug; 3(4):470-6. PubMed ID: 1908716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microencapsulation using poly(L-lactic acid) IV: Release properties of microcapsules containing phenobarbitone.
    Jalil R; Nixon JR
    J Microencapsul; 1990; 7(1):53-66. PubMed ID: 2308054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oestrone loaded poly(l-lactic acid) microspheres: preparation, evaluation and in vitro release kinetics.
    Parikh BV; Upadrashta SM; Neau SH; Nuessle NO
    J Microencapsul; 1993; 10(2):141-53. PubMed ID: 8331489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.